Mayday Fund   Report issue

Foundation Phase 2 Phase 3
Founded: New York NY United States (1992)

Organization Overview

First Clinical Trial
2007
NCT00715429
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Mayday Fund

Active Ingredients

Drugs in Phase 3 Trials (1)

sucrose (1 trial)

Drugs in Phase 2 Trials (2)

duloxetine (Cymbalta) (1 trial)

venlafaxine (effexor) (1 trial)

Drugs in Other Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 2)

Musculoskeletal Pain (Phase 2)

Neck Pain (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4